Whereas more than 3,100,000 men have at some point been diagnosed with prostate cancer and are still alive in the United States; Whereas 1 in 8 men in the United States will be diagnosed with prostate cancer in their lifetimes and 1 in 41 men in the United States will die from prostate cancer; Whereas prostate cancer is the most commonly diagnosed nonskin cancer and the second-leading cause of cancer-related deaths among men in the United States; Whereas the American Cancer Society estimates that, in 2023, 288,300 men will be diagnosed with, and more than 34,700 men will die of, prostate cancer; Whereas 40 percent of newly diagnosed prostate cancer cases occur in men under the age of 65; Whereas the odds of developing prostate cancer rise rapidly after age 50; Whereas African-American men suffer from a prostate cancer incidence rate that is significantly higher than that of White men and have more than double the prostate cancer mortality rate than that of White men; Whereas having a father or brother with prostate cancer more than doubles the risk of a man developing prostate cancer, with a higher risk for men who have a brother with the disease and the highest risk for men with several affected relatives; Whereas screening by a digital rectal examination and a prostate-specific antigen blood test can detect the disease at the earlier, more treatable stages, which could increase the chances of survival for more than 5 years to nearly 100 percent; Whereas only 32 percent of men survive more than 5 years if diagnosed with prostate cancer after the cancer has metastasized; Whereas there are typically no noticeable symptoms of prostate cancer in the early stages, making appropriate screening critical; Whereas, in fiscal year 2023, Congress appropriated $47,500,000,000 to the National Institutes of Health, including $7,104,159,000 for the National Cancer Institute; Whereas, in fiscal year 2023, Congress appropriated $110,000,000 for the peer-reviewed Prostate Cancer Research Program of the Department of Defense